Cargando…

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

NUCOLL43 is a novel ovarian clear cell carcinoma (O‐CCC) cell line that arose from a primary culture of a patient's malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45 hours and form colonies at high efficiency. They have a very high degree of loss of h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franklin, Miriam, Gentles, Lucy, Matheson, Elizabeth, Bown, Nick, Cross, Paul, Ralte, Angela, Gilkes‐Immeson, Connor, Bradbury, Alice, Zanjirband, Maryam, Lunec, John, Drew, Yvette, O'Donnell, Rachel, Curtin, Nicola J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144150/ https://www.ncbi.nlm.nih.gov/pubmed/30109783 http://dx.doi.org/10.1002/cam4.1724

Ejemplares similares

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer
por: Sharma Saha, Sweta, et al.
Publicado: (2021)

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
por: Gentles, Lucy, et al.
Publicado: (2019)

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2017)

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
por: Bradbury, Alice, et al.
Publicado: (2020)

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2016)

Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response
por: Bradbury, Alice, et al.
Publicado: (2022)

Influence of gene expression on survival of clear cell renal cell carcinoma
por: Berglund, Anders, et al.
Publicado: (2020)

Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas
por: Yao, Masahiro, et al.
Publicado: (2014)

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53(WT) Uterine Leiomyosarcoma
por: Chamberlain, Victoria, et al.
Publicado: (2021)

CCL2 as a potential therapeutic target for clear cell renal cell carcinoma
por: Arakaki, Ryuichiro, et al.
Publicado: (2016)

Etiologic heterogeneity of clear‐cell and papillary renal cell carcinoma in the Netherlands Cohort Study
por: van de Pol, Jeroen A. A., et al.
Publicado: (2020)

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2022)

Human microRNA similarity in breast cancer
por: Jing, Ying, et al.
Publicado: (2021)

Clear Cell Adenocarcinoma of the Ureter Similar to Clear Cell Renal Cell Carcinoma Histology
por: Watanabe, Kazuhiro, et al.
Publicado: (2021)

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
por: Gulati, Sakshi, et al.
Publicado: (2014)

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
por: Gulati, Shuchi, et al.
Publicado: (2022)

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma
por: Xu, Jianing, et al.
Publicado: (2019)

Preclinical evaluation of an unconventional ruthenium‐gold‐based chemotherapeutic: RANCE‐1, in clear cell renal cell carcinoma
por: Elie, Benelita T., et al.
Publicado: (2019)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm
por: Luo, Jun, et al.
Publicado: (2020)

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016)

Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma
por: Nakai, Takaaki, et al.
Publicado: (2017)

Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas
por: Arai, Eri, et al.
Publicado: (2015)

Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B
por: Liu, Junlong, et al.
Publicado: (2019)

Impairment of cell adhesion and migration by inhibition of protein disulphide isomerases in three breast cancer cell lines
por: Young, Henry S., et al.
Publicado: (2020)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Small Cell Carcinomas of the Uterine Cervix and Lung: Proteomics Reveals Similar Protein Expression Profiles
por: Egawa-Takata, Tomomi, et al.
Publicado: (2018)

Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma
por: Lin, Shitong, et al.
Publicado: (2020)

Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome
por: Arai, Eri, et al.
Publicado: (2009)

Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation
por: Li, Yuqing, et al.
Publicado: (2020)

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma
por: Eckel‐Passow, Jeanette E., et al.
Publicado: (2019)

Ubiquitin‐specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF‐κB pathway inactivation
por: Gui, Dingwen, et al.
Publicado: (2021)

MicroRNA‐194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma
por: Nofech‐Mozes, Roy, et al.
Publicado: (2016)

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
por: Motzer, Robert, et al.
Publicado: (2023)

Downregulation of NDUFB6 due to 9p24.1-p13.3 loss is implicated in metastatic clear cell renal cell carcinoma
por: Narimatsu, Takahiro, et al.
Publicado: (2015)

Patterns of distant metastases in patients with clear cell renal cell carcinoma––A population‐based analysis
por: Xue, Jianxin, et al.
Publicado: (2020)

An immature inhibin‐α‐expressing subpopulation of ovarian clear cell carcinoma cells is related to an unfavorable prognosis
por: Kusumoto, Shinya, et al.
Publicado: (2021)

A MUCINs expression signature impacts overall survival in patients with clear cell renal cell carcinoma
por: Meng, Hui, et al.
Publicado: (2021)

A prognostic nomogram based on competing endogenous RNA network for clear‐cell renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pinp405es9v1mte6ved0ek4qia